Go Pro
NASDAQ:RGC

Regencell Bioscience Q1 2026 Earnings Report

Regencell Bioscience logo
$5.65 +0.60 (+11.88%)
Closing price 07/14/2026 04:00 PM Eastern
Extended Trading
$5.66 +0.00 (+0.09%)
As of 07:25 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Regencell Bioscience EPS Results

Actual EPS
-$0.01
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Regencell Bioscience Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Regencell Bioscience Announcement Details

Quarter
Q1 2026
Time
After Market Closes
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

Regencell Bioscience Earnings Headlines

Ticker Revealed: Pre-IPO Access to "Next Elon Musk" Company
We’ve found The Next Elon Musk… and what we believe to be the next Tesla. It’s already racked up $26 billion in government contracts. Peter Thiel just bet $1 Billion on it.tc pixel
See More Regencell Bioscience Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Regencell Bioscience? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Regencell Bioscience and other key companies, straight to your email.

About Regencell Bioscience

Regencell Bioscience (NASDAQ:RGC) operates a Traditional Chinese medicine (TCM) bioscience company. It focuses on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, primarily attention deficit hyperactivity disorder and autism spectrum disorder. The company was incorporated in 2014 and is headquartered in Causeway Bay, Hong Kong.

View Regencell Bioscience Profile